VANDA PHARMACEUTICALS INC. Increase (Decrease) in Accounts Payable
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Accounts Payable of $796.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2015-07-31
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for the quarter ending 2015-06-30 was $142.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for the quarter ending 2015-03-31 was $654.00K, a 123.97% increase year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for the quarter ending 2014-12-31 was $288.00K, a 1.37% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for the quarter ending 2014-09-30 was $299.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for fiscal 2014 was $174.00K, a 53.48% decline from fiscal 2013.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for fiscal 2013 was $374.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for fiscal 2012 was -$709.00K, a 303.74% decline from fiscal 2011.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accounts payable for fiscal 2011 was $348.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2015-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $796.00K 10-Q · filed 2015-07-31 | $1.08M derived: sum of 3 quarters · filed 2015-07-31 | $1.38M derived: sum of 4 quarters · filed 2015-07-31 |
| 2015-03-31 | $654.00K 10-Q · filed 2015-05-07 | $942.00K derived: sum of 2 quarters · filed 2015-05-07 | $1.24M derived: sum of 3 quarters · filed 2015-05-07 | $536.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $587.00K derived: sum of 2 quarters · filed 2015-03-13 | -$118.00K derived: sum of 3 quarters · filed 2015-07-31 | $174.00K 10-K · filed 2015-03-13 |
| 2014-09-30 | $299.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | -$406.00K derived: sum of 2 quarters · filed 2015-07-31 | -$114.00K 10-Q · filed 2014-10-27 | $178.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-06-30 | -$705.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$413.00K 10-Q · filed 2015-07-31 | -$121.00K derived: sum of 3 quarters · filed 2015-07-31 | -$919.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-31 | $292.00K 10-Q · filed 2015-05-07 | $584.00K derived: sum of 2 quarters · filed 2015-05-07 | -$214.00K derived: sum of 3 quarters · filed 2015-05-07 | -$160.00K derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$506.00K derived: sum of 2 quarters · filed 2015-03-13 | -$452.00K derived: sum of 3 quarters · filed 2015-03-13 | $374.00K 10-K · filed 2015-03-13 |
| 2013-09-30 | -$798.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | -$744.00K derived: sum of 2 quarters · filed 2014-10-27 | $82.00K 10-Q · filed 2014-10-27 | -$721.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $880.00K 10-Q · filed 2014-08-08 | $77.00K derived: sum of 3 quarters · filed 2015-03-13 | -$522.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $826.00K 10-Q · filed 2014-05-08 | $23.00K derived: sum of 2 quarters · filed 2015-03-13 | -$576.00K derived: sum of 3 quarters · filed 2015-03-13 | $333.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | -$803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$1.40M derived: sum of 2 quarters · filed 2015-03-13 | -$493.00K derived: sum of 3 quarters · filed 2015-03-13 | -$709.00K 10-K · filed 2015-03-13 |
| 2012-09-30 | -$599.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $310.00K derived: sum of 2 quarters · filed 2013-11-08 | $94.00K 10-Q · filed 2013-11-08 | -$243.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $909.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $693.00K 10-Q · filed 2013-07-31 | $356.00K derived: sum of 3 quarters · filed 2014-02-25 | $352.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | -$216.00K 10-Q · filed 2013-05-10 | -$553.00K derived: sum of 2 quarters · filed 2014-02-25 | -$557.00K derived: sum of 3 quarters · filed 2014-02-25 | -$54.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | -$337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$341.00K derived: sum of 2 quarters · filed 2014-02-25 | $162.00K derived: sum of 3 quarters · filed 2014-02-25 | $348.00K 10-K · filed 2014-02-25 |
| 2011-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $499.00K derived: sum of 2 quarters · filed 2012-11-08 | $685.00K 10-Q · filed 2012-11-08 | $1.04M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $689.00K 10-Q · filed 2012-08-03 | $1.04M derived: sum of 3 quarters · filed 2013-02-26 | $317.00K derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $186.00K 10-Q · filed 2012-05-09 | $538.00K derived: sum of 2 quarters · filed 2013-02-26 | -$186.00K derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$372.00K derived: sum of 2 quarters · filed 2013-02-26 | -$1.78M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$724.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$2.13M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$1.40M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $1.91M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |